Skip to main content
MyDeficienciesMyDeficiencies
Research Preview — Unreviewed AI Research

Atorvastatin

HMG-CoA reductase inhibitor (statin)

Also sold as Lipitor.

Based on clinical, regulatory, and pharmacological evidence concerning atorvastatin and nutrient-related effects, the best-documented relationship concerns coenzyme Q10 (CoQ10): pooled trial evidence indicates statin therapy, including an atorvastatin-specific analysis, is associated with a reduction in blood CoQ10 concentration. Whether CoQ10 supplementation provides a clinical benefit is less settled, and that evidence is class-wide (statins generally) rather than atorvastatin-specific. A separate, well-documented food interaction involves grapefruit juice.

Researched 9/3/2026

Evidence summary

Qualifying findings
1
Interactions and timing
1
Searched, nothing found
1
Verified cited sources
3 of 3
Human review
Not yet reviewed
Analyze another medication Medication directory

Overview

Research Preview — Unreviewed AI Research

AI-assisted Research Preview - not yet human-reviewed and not part of Published Knowledge.

This is automated research that has not yet been reviewed by a person. It is not MyDeficiencies published knowledge, it is not medical advice, and it may be incomplete or wrong. It has been added to our editorial review queue.

HMG-CoA reductase inhibitor (statin). Based on clinical, regulatory, and pharmacological evidence concerning atorvastatin and nutrient-related effects, the best-documented relationship concerns coenzyme Q10 (CoQ10): pooled trial evidence indicates statin therapy, including an atorvastatin-specific analysis, is associated with a reduction in blood CoQ10 concentration. Whether CoQ10 supplementation provides a clinical benefit is less settled, and that evidence is class-wide (statins generally) rather than atorvastatin-specific. A separate, well-documented food interaction involves grapefruit juice.

Researched 9/3/2026 · Adversarial review ran: 3 confirmed, 2 scope corrections, 5 rejected.

3 of 3 cited sources were confirmed to exist as described. That check confirms the source is real, not that it supports the claim.

What the research found

Evidence for this exact medication is kept strictly apart from evidence that comes only from its drug class.

Direct evidence for this medication

Measured decrease in nutrient status

Coenzyme Q10 (CoQ10) — blood concentration

exact entity

Direct evidence for this medication

Pooled results from placebo-controlled trials, summarized in a 2015 meta-analysis, found that people taking statins — including a specific atorvastatin subgroup — had measurably lower blood CoQ10 concentrations than those on placebo.

2 cited sources and detail

Human studies that measured this nutrient in people taking this exact medication.

Relationship:
medication -> nutrient/biomarker status (Direction A)
Outcome measured:
Measured decrease in nutrient status
Study population:
human studies
Agreement:
2 supporting, 0 contradicting

What was measured: plasma/serum CoQ10 concentration (umol/L)

Proposed mechanism: Statins block an enzyme (HMG-CoA reductase) in a pathway the body also uses to make CoQ10, which offers a plausible biological explanation for the lower measured levels. A mechanism explains how an effect could occur. It is not itself a measured clinical outcome.

Adversarial review: a second, opposing review moved this finding to a weaker evidence category than it was first assigned.

2 of 2 cited sources were checked and found to support this specific claim. A source existing is not the same as a source supporting the claim.

Why it is here: Meta-analysis of RCTs with an atorvastatin-specific effect estimate; downgraded from an initial 'strong' read on Challenger review because clinical significance of the concentration change is explicitly called unresolved by the study authors.

Interactions and timing

How this medication and a nutrient affect each other's absorption, handling or timing. This is not depletion.

Medication and nutrient interaction

Grapefruit / grapefruit juice

exact entity

Interaction and timing

Atorvastatin's official prescribing information reports that grapefruit juice can raise blood levels of the medication. At an ordinary amount (about 240 mL, roughly one cup, per day), levels were shown to rise moderately (about 16-37% by different measures). The label specifically warns against drinking more than about 1.2 liters of grapefruit juice a day, since consumption at that excessive level has been associated with much larger increases in medication levels and a higher risk of muscle-related side effects.

1 cited source and detail

How this medication and this nutrient affect each other's absorption, handling or timing. This is not the same as depletion.

Relationship:
external factor (food) -> medication exposure (Direction B)
Outcome measured:
Medication and nutrient interaction
Study population:
human studies
Agreement:
1 supporting, 0 contradicting

What was measured: atorvastatin serum/plasma concentration (AUC/Cmax)

Proposed mechanism: Grapefruit juice can inhibit an intestinal enzyme (CYP3A4) involved in breaking down atorvastatin, which may allow more of the medication to reach the bloodstream. A mechanism explains how an effect could occur. It is not itself a measured clinical outcome.

1 of 1 cited sources were checked and found to support this specific claim. A source existing is not the same as a source supporting the claim.

Why it is here: Directly supported by the complete official Lipitor (atorvastatin calcium) FDA-approved label (DailyMed), independently retrieved in full this session, which provides exact quantitative data for both ordinary consumption (240 mL/day: AUC +37%, Cmax +16%) and excessive consumption (≥750 mL–1.2 L/day: AUC up to 2.5-fold, Cmax up to +71%). This is now primary, label-based evidence rather than a claim resting on an unavailable primary study.

Searched, no supporting evidence found

These relationships were searched for in this research run and no supporting evidence was found. Absence of evidence is not evidence of absence.

Vitamin E

unresolved scope

Searched, no supporting evidence found

No human study was found on atorvastatin's effect on vitamin E status. Official Lipitor labeling does not mention vitamin E anywhere. The only vitamin-E-related search result was an unrelated rat nephrotoxicity model using vitamin E and atorvastatin as co-treatments against a poisoning agent — not about atorvastatin affecting vitamin E status in humans. This is a documented negative search.

What was searched

We looked for this relationship and did not find supporting evidence. Absence of evidence is not evidence of absence.

Why it is here: Searched in this research run (WebSearch (general literature); Lipitor DailyMed label (full text searched)); no qualifying Atorvastatin-specific evidence was identified.

Evidence limitations

What this cannot tell you

  • A lower blood CoQ10 concentration is not the same as a diagnosed nutritional deficiency. The study authors themselves state that further research is needed to establish the clinical relevance of this change — this finding describes a laboratory measurement, not a confirmed clinical outcome.
  • This finding is directly supported by the complete official Lipitor prescribing information, which independently confirms both the ordinary-consumption and excessive-consumption quantitative effects. The 1999 research study historically cited for this interaction (Lilja et al.) was not independently retrieved in full text by this workbook and is kept only as historical/corroborating context — it is no longer needed as the primary support for this finding.
  • Search was not exhaustive across every possible vitamin E study design; absence of evidence is not proof of no relationship.
All research limitations for this run
  • Several nutrient dimensions remain unresearched beyond what this pass covered (e.g., selenium and other trace minerals). The Radhakrishnan 2015 vitamin D study's specific statin(s) were not confirmed as atorvastatin, and the Schwartz 2009 vitamin-D-supplementation finding remains unverified against its primary source.

AI-assisted Research Preview - not yet human-reviewed and not part of Published Knowledge. Educational information only. Not medical advice, diagnosis or treatment. Talk to your prescriber or pharmacist before changing any medication or supplement.

Sources

Only sources attached to information shown above are listed here.

  • LIPITOR (atorvastatin calcium) tablets, film coated — COMPLETE official FDA-approved label (DailyMed)

    N/A (regulator-approved labeling) · human study

    No public identifier recorded· identifier confirmed to exist (URL)

    https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10a7ba02-42d6-4cae-8904-b256e2da5496

  • Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and meta-analysis of placebo-controlled trials

    2015 · meta-analysis of RCTs (8 placebo-controlled treatment arms) · human study

    PMID 26192349· identifier confirmed to exist (PMID)

    https://pubmed.ncbi.nlm.nih.gov/26192349/

  • Atorvastatin Decreases the Coenzyme Q10 Level in the Blood of Patients at Risk for Cardiovascular Disease and Stroke

    2004 · prospective study (n=34, atorvastatin 80mg/day, 30 days) · human study

    PMID 15210526· identifier confirmed to exist (PMID)

    https://pubmed.ncbi.nlm.nih.gov/15210526/
  • Existence of a source and support for a claim are checked separately. A confirmed identifier means the record is real, not that it supports the statement it is cited for.

Questions for your clinician

These are conversation prompts, not findings about you.

  • Could Atorvastatin affect any nutrients over time in my situation?
  • Are there symptoms or risk factors that would make further evaluation appropriate?
  • Could diet, other medications, or health conditions affect this relationship?
  • Would laboratory testing be clinically appropriate for me?
  • Are there medication or supplement interactions I should understand?

Review status

Human review

Published Knowledge is human-reviewed. Research Previews are clearly labeled and have not yet completed human review.

MyDeficiencies is in a free, invitation-only beta. Nothing is for sale here and no payment is taken.

Derived from acceptance run artifacts/candidate-workbooks/MyDeficiencies_Claude_Cardiovascular_Candidate_Intelligence_Batch-001_FINAL-CORRECTED_2026-09-02.xlsx (373fbbf11d03).